A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes.  Here are four takeaways: 

In a population-based cohort study published in JAMA Ophthalmology, of 139,002 patients, those who used GLP-1s for six months or longer had a more than twofold increased risk of developing neovascular age-related macular degeneration compared to non-users.

Among the group who used GLP-1s, 0.2% developed nAMD versus 0.1% in the group who didn’t take GLP-1s. The study followed patients 66 and older with diabetes from January 2020 to November 2023 using comprehensive health data from Ontario, Canada’s public healthcare system.

In a joint statement issued July 9, the American A

See Full Page